Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.01 - $6.33
Previous CloseN/A
Volume51.94M
Average Volume (3M)2.86M
Market Cap
$338.00M
Enterprise Value$181.68M
Total Cash (Recent Filing)-$13.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.76
Next Earnings
May 13, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding127,548,420
10 Day Avg. Volume1,865,123
30 Day Avg. Volume2,863,005
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$9.00Price Target Upside238.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
AbSci News
---
Bulls Say, Bears Say
Bulls Say
PartnershipsAbsci has struck multiple pharma deals and achieved key design milestones, validating its technology and likely attracting further partnerships.
Pipeline DevelopmentAbsci's pipeline includes ABS-201 and ABS-301, targeting conditions with high unmet needs and representing an upside to the company's valuation.
TechnologyAbsci's AI-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity, setting itself apart from competitors.
Bears Say
Financial PerformanceQ4 revenues of $0.7M brought FY24 total revenues to $4.5M, below expectations.
Market CompetitionABS-101 showed the strongest odds of demonstrating a best-in-class clinical profile, potentially generating significant peak sales despite fierce competition in IBD.
Revenue And LossFor 4Q24, the company reported revenues of $0.7M, which was below the consensus estimate of $1.8M, and a net loss of $0.25 per share, compared to the consensus estimated net loss of $0.22 per share.
---
Ownership Overview
26.04% Insiders
18.03% Mutual Funds
<0.01% Other Institutional Investors
39.92% Public Companies and
Individual Investors
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.01 and its highest was $6.33 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $338.00M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is May 13, 2025 which is in 4 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Mar 18, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.224 by -$0.026.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.22.
How many shares outstanding does AbSci have?
AbSci has 127,548,420 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.224. Following the earnings report the stock price went down -3.247%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (238.35% Upside)
$9.00 (238.35% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.13%
12-Months-Change
Fundamentals
Return on Equity
-58.04%
Trailing 12-Months
Asset Growth
-8.90%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
---
ABSI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Absci's achievements in advancing their AI drug creation platform and securing strategic partnerships, which contribute to their long-term potential. However, increased R&D expenses and decreased quarterly revenue suggest some immediate financial challenges. The sentiment is balanced given the strong future outlook offset by current financial metrics.Read More>---
ABSI Stock 12 Month Forecast
Average Price Target
$9.00
▲(238.35% Upside)
Technical Analysis
Omeros
―
Zevra Therapeutics
―
Stoke Therapeutics
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
---